To identify the molecular changes in ovarian tumors that progress despite anti-VEGF therapy, we developed a preclinical model for adaptive resistance, wherein the tumor-bearing mice received anti-VEGF treatment for two months. This evidence concerns the gene VEGFA and ovarian neoplasm.